Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors
Arthritis Research & Therapy2011Vol. 13(1), pp. R25–R25
Citations Over TimeTop 15% of 2011 papers
Regina Rendas‐Baum, Gene V. Wallenstein, Tamás Koncz, Mark Kosinski, Min Yang, John Bradley, Samuel H. Zwillich
Abstract
For patients with prior exposure to TNF-α inhibitors, the likelihood of response to subsequent treatment with biologic agents declines with the increasing number of previous treatments with TNF-α inhibitors.
Related Papers
- → A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis(2018)20 cited
- → Economic impact of biologic utilization patterns in patients with psoriatic arthritis(2017)16 cited
- → Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: A case series(2010)18 cited
- [Fully human anti TNF-alpha monoclonal antibodies (adalimumab, golimumab)].(2007)
- → P433 A real-world observational study assessing treatment persistence in ulcerative colitis patients receiving anti-TNF treatment (golimumab or adalimumab)(2020)